03:49 AM EDT, 06/10/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said late Monday its Xywav drug met its primary endpoint of change in mean 24-hour ambulatory systolic blood pressure in a phase 4 trial of patients with narcolepsy.

Narcolepsy is a neurological sleep disorder that results in the inability to sleep continuously at night.

The study also achieved secondary endpoints, including mean changes in both ambulatory daytime and seated resting systolic blood pressure, the company said.

Xywav is already approved by the US Food and Drug Administration for the treatment of cataplexy or excessive daytime sleepiness in certain patients, the company said.

The results from the study "reinforce the importance of monitoring cardiovascular indicators, including blood pressure, and the need to minimize exposure to excess sodium in this at-risk population," Jazz Pharmaceuticals ( JAZZ ) said.